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ABSTRACT 
 
Background: Brain metastases are generally considered to be well-demarcated 
from the surrounding brain parenchyma, although infiltrative growth patterns have 
been observed. We systemically investigated infiltration patterns and expression of 
adhesion molecules in a large and well-defined series of autopsy cases of brain 
metastases. 
Methods: 97 autopsy specimens from 57 brain metastases patients (primary tumor: 
27 lung cancer, 6 breast cancer, 8 melanoma, 1 kidney cancer, 2 colorectal cancer, 
13 other) were evaluated for the patterns of invasion into surrounding brain 
parenchyma. Expression of integrins αv, cytoplasmic β3, αvβ3, αvβ5, αvβ6 and 
αvβ8, and of E and N cadherin were evaluated using immunohistochemistry.  
Results: Three main invasion patterns were seen: well-demarcated growth (29/57, 
51%), vascular co-option (10/57, 18%) and diffuse infiltration (18/57, 32%). There 
was no statistically significant association of invasion pattern with primary tumor 
type, although vascular co-option was most common in melanoma brain metastases 
(4/10). Invasion patterns of different brain metastases of the same patient were 
highly concordant (p<0.001; Chi Square test). Distance of infiltration from the main 
tumor mass ranged from 12.5 µm to 450 µm (median 56.2 µm) and was not 
significantly different between the vascular co-option and the diffuse infiltration 
groups. αvβ6 levels were significantly higher in the well-demarcated group than in 
the vascular co-option and the diffuse infiltration groups (p=0.033; Kruskal-Wallis 
test), respectively. αvβ5 expression in tumor cells was higher in brain metastases 
lesions previously treated with stereotactic radiosurgery (p=0.034; Chi square test). 
Conclusions: Distinct invasion patterns of brain metastases into the brain 
parenchyma are not specific for primary tumor types, seem to be influenced by 
expression of αv integrin complexes and may help to guide clinical decision making.  
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INTRODUCTION 
Brain metastases are a frequent complication in oncology and affect up to 40% of 
patients with metastatic cancer. 1 While the incidence of brain metastases showed a 
constant increase over the last decades, treatment options remain limited and rely 
mainly on local approaches like surgery, radiosurgery, or whole brain radiotherapy 
(WBRT). 2-4 Better understanding of the pathobiology of brain metastases may lead 
to novel treatments.  
Brain metastases are usually regarded as growing in a well-delineated fashion within 
the brain parenchyma. 5 This notion is mainly based on their neuroradiological 
presentation with relatively sharp demarcation of contrast-enhancing areas and a 
generally better delineation than that of malignant gliomas. However, the histological 
patterns of invasion in brain metastases have so far not been addressed in 
comprehensive studies, although infiltrative behavior has occasionally been noted. 
6,7 Clinically, infiltrative behavior with unclear resection margins is regularly noted by 
neurosurgeons and high local recurrence rates after (radio)-surgery have been 
reported for such cases. 8,9 
In general, cancer cells grow and invade solid tissues in different ways such as: 
expansive growth; multicellular migration; or individual cell migration. 10 Migration 
and invasion require complex regulation of specific molecules including adhesion 
molecules (e.g. integrins, cadherins), cytoskeletal components (e.g. actomyosin) and 
proteolytic enzymes (e.g. matrix metalloproteases, MMP) and others. 10-13 However, 
the types of invasive behavior of tumor cells have been mostly described in models 
of non-CNS tissues (e.g. skin) and it is unknown whether similar mechanisms are 
active in the brain, with its distinct microenvironment. The CNS microenvironment 
differs from that of other solid organs. The brain parenchmya is composed of highly 
specialized cells (neurons, astrocytes, oligodendrocytes, microglia) and its extra-
cellular matrix (ECM) has a distinct composition. It lacks constituents usually found in 
solid organs such as fibronectin and collagen, but it is rich in proteoglycans, 
tenascin, laminin, heparin/chondroitin/dermatan sulfates and hyaluronic acid. 14   
In this study we systemically characterized the invasion patterns of brain metastases 
and their correlation with the expression of several adhesion molecules in a series of 
autopsy specimens. Surgery specimens are not suitable for such studies since in 
most cases they include no or only little well-preserved brain tissue around the 
resection margin and are thus not sufficient for investigation of the invasion front and 
the interaction of cancer cells with the brain parenchyma.  
METHODS 
Patients 
All patients with histologically proven brain metastases who underwent brain autopsy 
between 1987 and 2011 were identified from the Neuro-Biobank of the Medical 
University of Vienna. Of each patient at least one representative formalin-fixed and 
paraffin-embedded tissue block containing tumor tissue and surrounding brain 
parenchyma was selected. Clinical and demographic data were retrieved by chart 
review. This study was approved by the ethics committee of the Medical University of 
Vienna (Ethics committee protocol number 078/2004).  
 
Evaluation of invasion patterns 
Evaluation of invasion patterns was performed on one routinely stained hematoxylin 
and eosin (H&E) section per tumor block. For enhanced visibility and better 
evaluation of single tumor cells, immunohistochemistry for cytokeratin (carcinomas) 
or HMGB45 (melanomas) and for evaluation of vascular structures 
immunohistochemistry for CD34 was performed on an automated horizontal slide-
processing system (AutostainerPlusLink, Dako, Glostrup, Denmark) using standard 
protocols in selected cases (Table 1). 15-17 Maximal invasion distance of tumor cells 
from the main tumor mass was microscopically measured on H&E slides with a grid 
of 25 µm length at 400x magnification.  
 
Immunohistochemistry and evaluation of integrins and cadherins 
Immunohistochemistry for αv subunit, cytoplasmic β3, and αvβ3, αvβ5, αvβ6 and 
αvβ8 complexes was performed with fully-automated multi-modal slide-staining 
system (BenchMark, Ventana Medical Systems, Strasbourg, France) as described 
previously. 18 In brief, an indirect biotin-avidin system with standard cell conditioner 1 
and EDTA pretreatment protocol were used. Signal amplification was achieved with 
a copper enhancer (iView DAB Detection Kit; Ventana Medical Systems). 19 
Immunohistochemistry for E cadherin and N cadherin was performed using an 
automated horizontal slide-processing system (AutostainerPlusLink/ Dako). In brief, 
antigen retrieval was performed with ph9 buffer (Flex TRS high, Dako). Slides were 
incubated with primary antibody for 1 h for N cadherin (Anti-N cadherin antibody, 
ab18203, abcam, Cambrige, UK, solution 1:500) and over night for E cadherin (Anti-
E cadherin antibody, ab15148, abcam, solution 1:30). Adequate positive and 
negative controls were included in each run. Table 1 lists antibodies, clones, dilution, 
positive controls and sources of reagents.  
Analyses of immunohistochemical staining of integrin αv subunit, cytoplasmic β3, 
αvβ3, αvβ5, αvβ6, αvβ8 complexes, and of E cadherin and N cadherin were 
performed by calculating the H-score. 20,21 In brief, intensity of membranous staining 
was multiplied by the percentage of cells showing a specific, complete, membranous 
immunoreactivity. Further, integrin and cadherin expression of the vascular 
structures of the surrounding brain parenchyma, tumor vessels, peritumoral vessel 
and stroma was evaluated semi-quantitatively and recorded as either positive or 
negative.  
 
Macroscopic autopsy and radiology 
For illustrative purposes, we retrospectively retrieved digitalized photographs of the 
macroscopic autopsy specimens and pre-mortem cranial MR images of the 
investigated patient cohort from the archives of our Neuro-Biobank and the 
Department of Neuroradiology where available.  
 
Statistics 
We performed exploratory analyses of correlation between invasion pattern and 
integrin and cadherin expression. For correlation of two binary variables Chi Square 
test was used. For correlation of median between invasion groups Kruskal Wallis test 
was performed. For correlation of invasion patterns with time from first diagnosis of 
brain metastases to death (overall survival time) we used the Kaplan-Meier method 
and the log-rank test. Patients, in whom brain metastases were detected at death 
were excluded from survival analysis. As the purpose of the study was exploratory, 
no adjustment for multiple testing was applied. 22 All statistics were calculated using 
statistical package for the social sciences (SPSS®) 20.0 software (SPSS Inc., 
Chicago, IL, USA). 
 
RESULTS 
Patients’ characteristics 
57 patients (26 female, 31 male) with a median age of 58 years (range 27-91) at 
death were included in the analysis. Overall 97 autopsy specimens were evaluated.. 
In all 57 patients one brain metastasis tissue block, in 30/57 (52.6%) patients tissue 
blocks of two distinct brain metastases and in 10/57 (17.5%) patients three tissue 
blocks of distinct brain metastases were available for investigation. In 18/57 (31.6%) 
patients diagnosis of brain metastases was made only at autopsy. 23/57 (40.4%) 
received treatment for brain metastases. First line treatment for brain metastases 
was surgery in 7/57 (12.3%) patients, stereotactic radiosurgery (SRS) in 8/57 
(14.0%), whole brain radiation therapy (WBRT) in 4/57 (7.0%) and chemotherapy in 
4/57 (7.0%) patients. Overall 7/57 (12.3%) of patients received WBRT during the 
course of disease, 7/57 (12.3%) received SRS of the brain metastasis investigated in 
this study and 17/57 (29.8%) patients received chemotherapy during the course of 
disease. 34/57 (59.6%) patients were treated with best supportive care upon 
diagnosis of brain metastases. According to autopsy protocols, brain metastases 
were the cause of death in 19/57 (33.3%) patients. Table 2 summarizes further 
patients’ characteristics and detailed compilation is given in supplemental Table 1.  
Invasion patterns of brain metastases  
Histomorphology 
We delineated three distinct invasion patterns: 29/57 (50.9%) brain metastases 
showed a distinct, well-demarcated border to the surrounding brain parenchyma 
(well-demarcated group); 10/57 (17.5%; Figure 1A) brain metastases showed 
distinct perivascular protrusions of multicellular tumor cell formations from the main 
tumor mass into the brain parenchyma (vascular co-option group, Figure 1B); 18/57 
(31.6%) brain metastases showed a diffuse infiltration of single tumor cells into the 
surrounding brain parenchyma (diffuse infiltration group; Figure 1C). Generally, the 
invasion pattern was consistent throughout major parts (>90% of the boarder) of the 
tumor/brain border in individual metastases.	 
In 30/57 (52.6%) cases, multiple distinct brain metastases of the same patient were 
available for investigation and the invasion type was in general highly congruent 
among the lesions (p<0.001 Chi Square test; Table 3).  
Median maximal measurable invasion distance of tumor cells from the border of the 
main tumor mass was 68.7 µm (range 12.5-125 µm) in the vascular co-option group 
and 56.2 µm (range 12.5 – 450 µm) in the diffuse infiltration group. The maximal 
measurable invasion distance was not different between the vascular co-option 
group and the diffuse infiltration group (p=0.486; t-test).  
Correlation with primary tumor type 
Brain metastases of melanoma tended to grow via vascular co-option more often 
than other primary tumors (4/8). The most frequent primary tumor in the well-
demarcated as well as in the diffuse infiltration group was lung cancer. Brain 
metastases of SCLC showed frequently a diffusely infiltrative growth (2/3), while 
NSCLC grew rather well-demarcated (13/24; 54.2%). Squamous NSCLC were more 
common in the well-demarcated group (4/6), while adenocarcinoma NSCLC was 
equally represented in the well-demarcated (5/12; 41.7%) and the diffuse infiltration 
group (5/12; 41.7%). See Table 2 for correlation of invasion patterns with primary 
tumor type. 
Correlation with treatment 
Complete information on applied therapies after diagnosis of brain metastases was 
available for 55/57 (96.5%) patients. No statistically significant association was 
observed between first-line or any-line brain metastases treatment and invasion 
patterns (Table 2). In the diffuse infiltration group a higher proportion of patients had 
received WBRT at any time point (4/18; 22%) compared to the well-demarcated 
group (2/28; 7.1%) or the vascular co-option group (1/10). Further, a higher 
proportion of patients had received chemotherapy during their course of disease in 
the diffuse infiltration group (8/17; 47.1%) than in the well-demarcated (8/28; 28.6%) 
or the vascular co-option group (1/10).  
Correlation with clinical characteristics 
Survival times from first diagnosis of brain metastases were available in 37 patients. 
Median survival from diagnosis of brain metastases was 2.0 months in the well-
demarcated group (n=19), 1.8 months in the vascular co-option group (n= 5) and 1.8 
months in the diffuse infiltration group (n= 13). There was no statistically significant 
correlation of invasion pattern with survival time from diagnosis of brain metastases 
in this small cohort (p=0.945, log rank test). Patients in the well-demarcated group 
had more often a singular brain metastases at first diagnosis of brain metastases 
(52%) than the vascular co-option (33.3%) or diffuse infiltration group (35.7%; 
p=0.483, Chi square test). Extracranial metastases were present in 19/57 (33.3%) 
patients. No difference in the presence of extracranial metastases was observed 
between the three invasion patterns (p=0.781; Chi square test). In the cohort of all 
56 patients, there was no significant association of invasion pattern with survival time 
(p= 0.825, log-rank test). Correlation with macroscopic pathology findings and 
neuroradiology 
Illustrative correlations of macroscopic pathology and neuroradiological findings with 
histological invasion patterns are shown in Figure 1. The low number of available 
macroscopic photographs (n=4) and pre-mortal neuroradiological images (n=5) 
precluded systematic correlation with histological findings. 
Integrin expression 
General description 
av integrins showed strong membranous expression on tumor, vascular, and stromal 
cells in variable fractions of cases. In general, the majority of specimens showed with 
homogenous av integrin expression patterns throughout the tumor tissue, except for 
αvβ8 expression, which was absent in the majority of specimens (supplemental 
Table 1). However, regional accentuation of integrin expression was observed in 
some specimens. Accentuated expression in perivascular tumor cells was observed 
in 11/57 (19.3%), 9/57 (15.8%) and 4/57 (7.0%) for αv subunit, αvβ6 and αvβ5, 
respectively. Peri-necrotic overexpression of αvβ6, αv subunit and αvβ5 was found in 
4/57 (7.0%), 2/57 (3.5%) and 2/57 (3.5%) cases, respectively (Figure 2). 
Analyzing expression on vascular structures, we observed αvβ5 integrin expression 
on all (57/57, 100%) vessels including tumoral and peritumoral vessels as well as the 
vascular structures of the surrounding brain parenchyma. αvβ3 expression was not 
observed on the vascular structures of the surrounding brain parenchyma, except 
randomly on some larger vessels of the meninges. Prominent expression of αvβ3 
was observed on angiogenic, sprouting vessels with multi-layered endothelium within 
the tumor and in the peritumoral area. In 30/57 (52.6%) specimens, immunoreactivity 
for αvβ3 of the angiogenic tumor vessels was observed and in 29/57 (50.9%) 
specimens, angiogenic vessels in the peritumoral area showed specific 
immunoreactivity for αvβ3. Specific immunoreactivity for β3 subunit was observed in 
angiogenic tumor vessels of 46/57 (80.7%) specimens and in angiogenic vessels in 
the peritumoral area of 45/57 (78.9%) specimens (Figure 3).  The expression 
detected for the v3 complex was generally lower than for the 3 cytoplasmic 
domain.  The 3 chain is on two integrin complexes, v3 and gpiibiiia (the platelet 
fibrinogen receptor). The tissue localization suggested that the staining of 3 was not 
due to platelet deposits or aggregates. The v3-antibody used (EM22703) binds 
preferentially particular ligated conformation of v3, while the cytoplasmic-3 
antibody (EM00212) does not discriminate 18. This may explain the difference in 
staining results between these antibodies. 
Fibrous tumoral stroma was observed in 32/57 (56.1%) specimens and showed 
expression of αv subunit (32/32, 100%), αvβ3 (2/32, 6.3%), αvβ5 (28/32, 87.5%) and 
αvβ6 (6/32, 18.8%).  
Relative overexpression of v integrins at the invasion front was not consistently 
found, but only in some specimens (αv subunit: 8/57, 14.0%: αvβ5: 8/57, 14.0%; 
αvβ6: 8/57, 14.0%). 
 
Correlation with invasion patterns  
Median H-score of αvβ6 was significantly higher in the well-demarcated (median 90; 
range 0-300) than in the vascular co-option (median 0; range 0-120) and the diffuse 
infiltration group (median 30; range 0-120; p=0.033; Kruskal Wallis test). No 
correlation of invasion pattern and median H-score of αv subunit, αvβ3, αvβ5, αvβ8 
or β3 subunit was observed. 
 
Correlation with therapy 
Brain metastases previously treated with stereotactic radiosurgery presented more 
frequently with αvβ5 expression in the tumor cells (6/7) than specimens without prior 
stereotactic radiosurgery (21/49, 42.9%; p=0.034; Chi square test). Furthermore, 
median αvβ5 H-score was significantly higher in brain metastases with prior 
stereotactic radiosurgery (60 vs. 0; p=0.05, Mann Whitney U test). No correlation 
between stereotactic radiosurgery treatments and αv subunit, αvβ3, αvβ6, αvβ8 or 
β3 subunit expression was observed. Prior WBRT or chemotherapy did not show a 
significant correlation with expression of any of the integrin subunits investigated in 
this study. 
Cadherin expression  
42/57 (73.7%) tumor specimens showed expression of E cadherin, 10/57 (17.5%) of 
N cadherin and 6/57 (10.5%) showed expression of both cadherins. No significant 
correlation of median H-score of E cadherin or N cadherin and invasion pattern or 
primary tumor types was observed. 9/57 (15.8%) specimens showed increased E 
cadherin expression at the invasion front. 3/57 (5.3%) specimens showed 
overlapping increased expression at the invasion front of E cadherin and αv, 2/57 
(3.5%) overlapping expression with αvβ5 and 1/57 (1.8%) specimen overlapping 
expression with αvβ6 at the invasion front. No cadherin expression was observed in 
the tumor stroma or vascular structures. 
DISCUSSION 
Brain metastases are an increasing challenge in oncological practice, as survival in 
many types of solid cancers is increased by novel treatment strategies. The 
dominant treatment strategies for brain metastases are local and include surgery and 
radiosurgery. The benefit from local treatments is likely to be heavily impacted by the 
degree to which macroscopically focal disease is truly focal on a microscopic level. 
Accordingly, the brain metastasis/brain interface may assume major prognostic 
significance. 
 
Here, we delineate three distinct invasion patterns of brain metastases: well-
demarcated growth, vascular co-option and diffuse infiltration. We found a high 
fraction of cases showing invasive growth via vascular co-option (18%) or single cell 
infiltration (32%). These surprising findings challenge the general notion that brain 
metastases predominantly grow in an expansive and well-delineated fashion, but are 
in good agreement with previous results from experimental studies, smaller and less 
comprehensive investigations on human tissue samples, and from clinical 
observations.  
 
In half of our cases, we observed expansive growth of an outwardly extending tumor 
mass within the brain parenchyma. αvβ6 expression levels were significantly higher 
in this group of well-demarcated tumors. Integrin αvβ6 is not expressed in healthy 
adult epithelia but is up-regulated in cancer and has been shown to modulate 
invasion and inhibit apoptosis.23 However, the exact role of αvβ6 in cancer 
pathobiology and in particular in brain metastases remains to be determined.  
 The vascular basement membrane may act as guiding track for perivascular growth 
of cell collectives. Our results indicate that this invasion behavior is present not only 
in mesenchymal and epithelial tissues, but also occurs in the distinct 
microenvironment of the CNS. In line with previous studies we observed vascular co-
option most commonly in melanoma brain metastases, however, we found it also in 
other tumor types such as NSCLC adenocarcinoma. 24-26  
 
Single cell infiltration into the brain parenchyma of brain-metastatic tumor cells has 
previously been reported to be characteristic for SCLC. 7 Our data show that this 
invasion patterns is not uncommon also in brain metastases of other tumor types 
including NSCLC adenocarcinoma/ squamous cell carcinoma, breast cancer and 
melanoma. The high fraction of brain metastases cases showing infiltrative growth 
has implications for local therapy options and highlights the need for including a 
safety margin beyond the neuroradiologically visible tumor borders.6 In our study, 
depth of invasion into the CNS parenchyma from the main tumor mass reached up to 
450 µm. Of note, stereotactic radiosurgery uses no margins for treatment, but at 0.4 
mm from the prescription isodose line near full dose is delivered, and therefore, the 
magnitude of invasion has no clear consequence on stereotactic radiosurgery 
practice. The selection of patients in need for an extended local treatment approach 
is challenging as the current neuro-radiological techniques cannot precisely visualize 
the invasion distance of a given tumor. However, we previously demonstrated that 
the extent of peritumoral brain edema might function as a surrogate marker for 
infiltrative tumor growth, as little brain edema was significantly more common in 
infiltrative brain metastases and correlated with impaired patient survival times. 8 
Further prospective studies need to address the prognostic implications of brain 
metastases invasion patterns in more detail. 
	
We did not observe a statistically significant correlation of treatment modality with 
invasion pattern in our cohort. However, a higher proportion of patients in the diffuse 
infiltration group had received prior radiation or chemotherapy.. As our sample size is 
not adequate for firm statistical conclusions, we cannot exclude that radio- or 
chemotherapy may select for or produce tumor cell with a higher infiltrative potential, 
similarly to some observations in primary tumors and gliomas. 27 Interestingly, brain 
metastases lesions previously treated with stereotactic radiotherapy showed higher 
expression of αvβ5, a finding which is well in line with previous reports showing that 
this molecule is essential for tumor growth in preirradiated stroma. 28 Further, we 
observed a high consistency of invasion behavior between the growth patterns of 
different brain metastases in individual patients. This again may indicate that intrinsic 
molecular features of metastases originating from a given primary tumor correlate 
with certain invasion patterns. 
 
Our results have to interpreted with caution since the small sample sizes often do not 
allow firm statistically conclusions. Herein, we concentrated on the descriptive 
presentation of our results. However, it has to be taken into account that autopsy 
samples of BRAIN METASTASES are very rare and our series displays a rather 
large cohort compared to previously published studies on autopsy specimens. 6,7 
 
We noted prominent expression of αv integrins in many brain metastases cases. 
This underscores the important function of this class of molecules in metastatic 
cancer. Currently, several integrin inhibitors are under clinical development and 
promising activity was shown in some of the most frequent primary tumors of brain 
metastases such as NSCLC and melanoma. 29-31 Interestingly, the anti-αv-integrin 
antibody intetumumab reduced brain metastases outgrowth in mice after intra-carotid 
infusion of brain-seeking HER2-postive breast cancer cells. 32 Thus, clinical trials 
specifically investigating the potential of integrin inhibitors for prophylaxis and 
treatment of brain metastases seem warranted. 
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FIGURE LEGENDS 
Figure 1: Distinct invasion patterns in human brain metastases. A example of well-
demarcated invasion (Patient 5, NSCLC, supplemental Table 1): Aa H&E slide 
(magnification X 1.25); Ab: Invasion front of well-demarcated brain metastasis 
(magnification x 400); Ac: Macroscopic sample of well-demarcated brain metastasis; 
Ad MRI contrast-enhanced T1-weighted sequence sample of well-demarcated brain 
metastasis; B example of vascular co-option (Patient 13, melanoma, supplemental 
Table 1): Ba: H&E slide (magnification x 1.25); Bb: CD34 immunohistochemistry of 
vascular co-option (magnification X 400); Bc: Macroscopic sample of brain 
metastasis growing via vascular co-option; Bd MRI contrast-enhanced T1-weighted 
sequence sample of brain metastasis growing via vascular co-option; C example of 
diffuse invasion (Patient 2, SCLC, supplemental Table 1); Ca H&E of brain 
metastasis (magnification x 1.25); Cb: CD18 cytokeratin staining showing diffusely 
infiltrating tumor cells; Cc: Macroscopic sample of diffuse infiltrating brain metastasis; 
Cd MRI contrast-enhanced T1-weighted sequence sample of diffuse infiltrating brain 
metastasis.  
Figure 2: Integrin expression patters: A: αv subunit expression (Patient 5, NSCLC, 
supplemental Table 1); B: αvβ5 expression with accentuation around a vessel 
(Patient 5, NSCLC, supplemental Table 1); C: αvβ5 expression in a brain metastasis 
growing via vascular co-option (Patient 13, melanoma, supplemental Table 1); D 
αvβ6 expression with accentuation around necrosis, star marks necrosis (Patient 5, 
NSCLC, supplemental Table 1).  
Figure 3: Integrin expression in vascular structures. A: αvβ3 expression on tumor 
vessel, arrow marks a vessel in the peritumoral area without αvβ3 expression 
(Patient 5, NSCLC, supplemental Table 1), B: αvβ3 expression in glomeruloid-like 
vessels of the peritumoral area, star marks the tumor tissue, the cross marks the 
surrounding cerebellum (Patient 8, SCLC, supplemental Table 1), C: αvβ3 
expression in a vessel with vascular co-option Patient 13, melanoma, supplemental 
Table 1), D: CD34 immunohistochemistry of the case shown in B, illustrating the 
peritumoral sprouting vessels (Patient 8, SCLC, supplemental Table 1).  
 



